UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/articles/2026-06-17/uniqure-resolves-huntington-s-dispute-will-file-for-us-approval)